- Home
- PROK vs BLFY Comparison
PROK vs BLFY Comparison
Compare PROK & BLFY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PROK | BLFY |
|---|---|---|
| Founded | 2015 | 1939 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Commercial Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 417.1M | 185.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PROK | BLFY |
|---|---|---|
| Price | $2.52 | $12.69 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 1 |
| Target Price | $7.40 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 1.3M | 261.7K |
| Earning Date | 11-10-2025 | 01-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $744,000.00 | ★ $44,731,000.00 |
| Revenue This Year | $956.51 | $19.85 |
| Revenue Next Year | N/A | $20.18 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 11.52 |
| 52 Week Low | $0.46 | $7.61 |
| 52 Week High | $7.13 | $13.13 |
Technical Indicators
Market Signals| Indicator | PROK | BLFY |
|---|---|---|
| Relative Strength Index (RSI) | 54.21 | 75.35 |
| Support Level | $2.33 | $12.59 |
| Resistance Level | $2.59 | $13.13 |
| Average True Range (ATR) | 0.15 | 0.30 |
| MACD | 0.05 | -0.10 |
| Stochastic Oscillator | 84.91 | 62.37 |
Price Performance
Historical ComparisonAbout PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
About BLFY Blue Foundry Bancorp
Blue Foundry Bancorp is a full-service bank. Its business consists of originating one-to-four-family residential, multi-family, and non-residential real estate mortgages, home equity loans and lines of credit, and commercial and industrial loans. It attracts retail deposits from the general public in the areas surrounding its banking offices, through its borrowers, and through its online presence, offering a wide variety of deposit products. The bank also invests in securities. Its revenues are derived from interest on loans and, to a lesser extent, interest on mortgage-backed and other investment securities. The company's sources of funds are deposits, principal, and interest payments on loans, securities, and borrowings from the Federal Home Loan Bank of New York.